1991). The development of new therapeutic strategies such as gene therapy may therefore be of great promise. One potential gene therapeutic approach for malignant tum ors involves inhibition of tumor angiogenesis Kong and Crystal, 1998) .
Antiangiogenesis relies on the concept that the growth of solid tumors is dependent on their ability to satisfy their demand for nutrients and oxygen (Folkman, 1995a; Folkman et al., 1966) . To meet this dem and tumors must be able to generate new blood vessels, through a process termed angiogenesis (Folkman, 1995b) .
Angiogenesis is a complex process that includes activation, proliferation, and migration of endothelial cells, disruption of the capillary basal membrane, and form ation of vascular tubes and networks (Folkman, 1995a) . In tum ors, angiogenesis can be triggered by various proteins secreted by tumor cells or macrophages (Folkman and Klagsbrun, 1987; Klagsbrun and D' Amore, 1991) . Vascular endothelial growth factor (VEGF) appears to be the most relevant angiogenic factor in solid tumors (Kim et al., 1993; Senger et al., 1993; Saleh et al., 1996) . Consistent with this concept, VEGF is upregulated in most human tumors (Plate et al., 1992; Brown et al., 1993a Brown et al., ,b, 1995 Senger et al., 1993; Suzuki et al., 1996) . The mechanism of VEGF upregulation is not fully understood but growing evidence suggests that hypoxia is the major driving force (Shweiki et al., 1992; Damert et al., 1997) .
VEGF binds to endothelial cells via interaction with highaffinity tyrosine kinase receptors Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2), found almost exclusively on endothelial cells De Vries et al., 1992; Terman et al., 1992; Millauer et al., 1993) . The selective expression of VEGF receptors ensures that VEGF action is confined to the endothelial cells.
The fms-like tyrosine receptor (Flt-1, VEGFR-1) consists of seven IgG-like repeats in the ligand-binding domain, a single transmembrane dom ain, and a tyrosine kinase domain . The function of Flt-1 is still speculative. Although necessary for normal vascular developm ent (Fong et al., 1995) , there is no evidence of the participation of Flt-1 in endothelial cell migration or proliferation (Waltenberger et al., 1994) .
Fetal liver kinase (Flk-1, VEGFR-2) is the mouse homolog of kinase insert domain-containi ng receptor, KDR, in humans (Matthews et al., 1991; Terman et al., 1992; Millauer et al., 1993) . VEGFR-2 has a similar arrangement of extracellular, transmembrane , and intracellular domains than VEGFR-1. In contrast to VEGFR-1, VEGFR-2 is phosphorylated and VEGFR-2-expressing cells proliferate after addition of VEGF Waltenberger et al., 1994) .
Previously, upregulation of VEGF and VEGF receptors during glioma development and progression has been described. VEGF receptors were not detected in normal human brain vascular cells, whereas expression was increased in the tumor vasculature (Plate et al., 1993 Plate and Risau, 1995) . Thus, the upregulation of VEGF receptors appears to be a critical event that regulates glioma angiogenesis.
The relevance of the VEGF/VEGFR-2 ligand/receptor system for tumor angiogenesis was confirmed in different experimental settings (Millauer et al., , 1996 Strawn et al., 1996; Skobe et al., 1997) . Millauer et al. (1994) used retrovirus-mediated gene transfer of a dominant-negati ve VEGFR-2 to block endogeneous wild-type receptor function. Although an effect of dom inant-negative VEGFR-2 on tumor growth was observed, further investigations are warranted to develop this laboratory model into clinically applicable gene therapy. In this study we explored the efficacy of dom inant-negative VEGFR-2 receptor antiangiogenic therapy in a syngeneic subcutaneous and intracerebral rat glioma model.
In addition, we investigated the safety of retrovirus-medi ated gene transfer encoding a truncated VEGFR-2.
M ATERIALS AND M ETH ODS

Recombinant vectors
Production of LXflk-1TM vector has been previously described . In brief, the flk-1TM mutant lacks 561 C-terminal amino acids of the intracellular kinase domain. The flk-1TM cDNA was subcloned into pLXSN retroviral plasmid. Expression of the cDNAs is driven by the 59 Moloney murine sarcoma virus long term inal repeat (LTR). The vector also contains an internal sim ian virus 40 (SV40) promoter that drives a neomycin resistance gene (neo r ) (Miller and Rosman, 1989) .
Cells and cell cultures
GPE LXflk-1TM is a GP1 E86 ecotropic virus-packaging cell line that produces virus carrying flk-1TM . GPE LXNULL is a sim ilar virus-packaging line with pLXSN vector without transgene, and is used as control. GPE LXNULL virus-producing cells were obtained by calcium phosphate transfection of GP-E86 as described (Ausubel, 1997) . Individual colonies were harvested and tested for virus production and vector integration by Southern blot analysis. Titers of virus-producing cell lines were about 1 3 10 6 colony-forming units (CFU)/ml. GS-9L (rat gliosarcoma) cells were a gift of T. Budd (St. Lawrence University, New York). GS-9L-flk-1TM cells were engineered by infecting GS-9L with virus supernatant containing flk1-TM. Transfected cells were selected in G418 (Pansystems, Aidenbach, Germany) (1 mg/ml). Clones with high expression levels of flk-1 were screened by Northern and Western blot. Expression of cell surface receptors was determ ined by an 125 I-labeled VEGF binding study as described (Clauss et al., 1996) . Growth curves in vitro of GS-9L-flk-1T M were determined as described (Saleh et al., 1996) and were sim ilar to those of parental cells.
Virus-producing cells were cultured in 10% fetal bovine serum (FBS) in Dulbecco' s modified Eagle' s medium (DMEM; Life Technologies, Gaithersburg, MD) containing G418. GS-9L and GS-9L-flk-1T M cells were cultivated in 10% FBS±RPMI (Life Technologies). For in vivo injections, cells were trypsinized, centrifuged, rinsed twice with phosphatebuffered saline (PBS), counted (Casy 1; Schärfe Systems, Reutlingen, Germany), and resuspended in PBS for inoculation.
Preparation of flk1-TM virus-containing concentrated supernatant
Viral stock was obtained from cultures that had been grown to near 80% confluence in selection medium, then maintained in medium lacking G418 for 24 hr. The supernatant from GPE LXflk-1TM virus-producing cells was harvested, filtered through a 45-m m pore size filter, and stored at 2 70°C. To concentrate the virus supernatant, stocks were thawed and centrifuged for 20 min at 14,000 rpm in a JA-14 rotor (Beckman Instrum ents, Palo Alto, CA) at 4°C. The supernatant was transferred into new sterile bottles and centrifuged for 16 hr at 14,000 rpm. The supernatant was discarded and the pellet was resuspended in 0.1% of the original volume in DMEM. The virus titer was 4.5 3 10 7 CFU/ml.
Intracerebral tumor implants
All procedures with animals were performed according to the institutional guidelines for use of laboratory anim als. Female Fischer 344 rats (150±180 g) (Charles River Laboratories, Wilmington, MA) were used for syngeneic GS-9L implants. Transplantation has been previously described (Plate et al., 1993) . For coim plantation experiments, tumor cells (4 3 10 5 ) were stereotactically inoculated either alone or mixed with virus-producing cells in a final volume of 20 m l. Virus-containing concentrated supernatant (VCS, 10 m l) was coinoculated with 4 3 10 5 GS-9L. The rats were divided into groups described in Table 1 .
To determ ine the efficacy of an antiangiogenic therapy us- 5 GPE LXflk-1TM were implanted intracerebrally. Three and 6 months after cell injection, rats (two animals at each time point) were sacrificed and tissues were collected as described below.
Animals were observed daily for the development of symptoms associated with progression of intracerebral tumors. Animals displaying advanced symptoms (loss of appetite, leaning, dehydration, and/or significant weight loss) were sacrificed by cardiac perfusion with PBS. The brains were removed and analyzed histologically. From two animals of each group, the brains were divided into two parts so that both parts contained tumor tissue. One part was fixed in 4% paraformaldehyd e for 5 days, and reserved for histological examination. The other part of the brain and heart, kidney, liver, lung, and spleen were immersed in cryovials and immediately frozen in liquid nitrogen. Rats without symptoms after 3 months of tumor cell implantation were excluded from the study.
Subcutaneous tumor implants
To investigate the influence of tumor size on tumor growth inhibition after GPE LXflk-1TM administration, six groups of 344 Fischer rats (n 5 6 for each group) were injected subcutaneously with 10 6 GS9L tum or cells in 500 m l of PBS in the right flanks. GPE LXflk-1TM cells (10 6 ) were inoculated every 3 days, with the beginning of treatment being at a different time point for each group: day 0 (group II), day 3 (group III), day 9 (group IV), day 18 (group V), and day 36 (group VI). Control tumors were injected with PBS alone (group I). On day 39, rats were sacrificed and tumors were removed for histological analysis. To quantify tum or growth, two perpendicular diameters of the resultant subcutaneous tumors were measured with calipers every 3 days. The inhibition was calculated by comparing the tumor size of groups injected with GPE LXflk-1TM with that of the control group.
DNA isolation and analysis
DNA was isolated from tissue by overnight incubation at 55°C with proteinase K (0.5 mg/ml; Boehringer GmbH, Mannheim, Germany) in 50 mM Tris-H Cl (pH 8.0), 100 mM ETDA, 100 mM NaCl, 1% sodium dodecyl sulfate (SDS). Each mixture was subsequently extracted two times with equal volumes of buffered phenol±chloroform±isoam yl alcohol (25:24:1). DNA was precipiated with 2 vol of ethanol and 0.5 vol of 7.5 M ammonium acetate, pelleted at 12,000 3 g in a microcentrifuge for 10 min, rinsed twice with 70% ethanol, and dried at room temperature in a laminar flow hood. The DNA pellet was resuspended in 80 m l of water with RNase A (0.1 mg/ml; Sigma, St. Louis, MO) and incubated at 37°C for 30 min. To remove digested RNA, DNA was again precipitated as described above. The DNA pellet was rehydrated in 80 m l of water. OD 260 readings were taken to determine the DNA concentration. A 1-m g sample was run on a 0.8% agarose gel to confirm visually the concentration of sam ples and DNA purity.
Southern blot analysis
Sample DNA (10 m g/lane) was digested by overnight incubation with EcoRI (10 IU/m g; Boehringer GmbH) and electrophoresed in a 1% agarose gel in 13 TAE buffer at 35 V. DNA was transferred by a standard Southern procedure to a Duralon membrane (Stratagene, La Jolla, CA). After UV crosslinking, membranes were hybridized for 1 hr in Quick Hyb (Stratagene) at 68°C with randomly primed, 32 P-labeled, 760-bp neo r fragm ent.
Detection of neo r gene by PCR
For amplification of the neo r gene, the following oligonucleotide primers were used as described (Kiem et al., 1994) :
Sense prim er Neo R 350: 59 AAGAGACAGGATGAAG-GATCG 39
Antisense prim er Neo R 1150: 59 CAGAAGAACTCGT-CAAGA 39
These sequences amplified an 800-bp fragment. DNA samples (1 m g) were amplified by using 2.5 U of Taq polymerase (Qiagen, Hilden, Germany) per 50-m l reaction mixture with 150 ng of each primer. The thermocycler profile used included initial denaturation at 94°C for 4 min, followed by 30 cycles each consisting of 94°C for 1 min, 50°C for 2 min, and 72°C for 4 min. Aliquots (10 m l) were separated in a 1% agarose gel and transferred to nylon membrane (Duralon-UV; Stratagene) by a Southern blotting method (Ausubel, 1997) . neo r -specific polymerase chain reaction (PCR) products were detected by hybridization of a 32 P-labeled DNA probe. This probe was synthesized from a plasmid fragment containing the neo r sequence by PCR amplification. Primers used in this synthesis were as follows:
Sense primer Neo R 450: 59 ACAAACAGACAATCGGCT-GCT 39 Antisense primer Neo R 1027: 59 GCCAACGCTATGTCCT-GATA 39
The resultant 577-bp fragment would hybridize to neo r fragments amplified by the previous primers, but should not hybridize to the primers themselves.
RNA probe generation by in vitro transcription
To determine the infection rate of tumor/endothelial cells in tumor and normal tissue, in situ hybridization was conducted using a neo r probe and an Flk-1 probe. A 760-bp neo r PCR fragm ent in PGEM-T (Promega, Madison, WI) and a 2.6-kb EcoRI±BamHI fragm ent of the murine flk-1 cDNA encoding part of the extracellular domain in PGEM3 (Promega) were used to generate nonradioactive antisense and sense RNA probes by in vitro transcription. After linearization of the plasmid, single-stranded ª runoffº transcripts were synthesized from the SP6/T7 polymerase promoters by using digoxigenin-label ed UTP as a substrate according to the manufacturer instructions (DIG RNA-labeling kit; Boehringer GmbH). After determination of concentration and labeling efficiency, digoxigenin-labeled probes were stored at 2 20°C or directly used for in situ hybridization analysis.
In situ hybridization
Paraffin-embed ded 4-m m sections were deparaffinized, followed by digestion with proteinase K (10 mg/ml) for 15 min at 37°C. After postfixation with 4% paraformaldehyd e, sections were acetylated with 0.1 M triethanolamine and 0.25% acetic anhydride for 10 min at room tem perature. Prehybridization solution containing 43 SSC (13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 50% deionized form amide, 2% SDS, 53 Denhardt' s solution, 10% dextran sulfate, and yeast tRNA (0.5 mg/ml) was applied for 1.5 hr at 48°C. The RNA sense/antisense probe concentration for hybridization was 0.1±0.5 ng/ml of initial transcript. Tissue sections were incubated in a humidified chamber under glass coverslips at 48°C overnight. Posthybridizatio n stringency washes at 48°C included 23 SSC for 30 min, 23 SSC plus 0.1% SDS for 5 min, 0.13 SSC plus 0.1% SDS for 15 min. Each wash was carried out twice. After RNase A treatment (2.5 mg/ml in 23 SSC) for 5 min at 37°C hybridized probes were detected by anti-DIG antibody conjugated to alkaline phosphatase (Boehringer GmbH) diluted 1:500 for 1 hr at room temperature. Nitroblue tetrazolium/ 5-brom o-4-chloro-3-indoly l phosphate solution was used as color substrate in 0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5. Color reaction times ranged from 6 to 8 hr, after which slides were rinsed in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
Immunohistochemistry
Immunohistoch emical stainings were perform ed with von Willebrand factor (Dakopatts, Copenhagen, Denmark) (diluted 1:100), a rat-specific CD3 marker (IF4; Serotec, Oxford, England) (diluted 1:1000), and a rat-specific microglia-macr ophage marker (Ed-1; Serotec) (diluted 1:1000). Staining was carried out using immunoperox idase staining kits for rabbit and mouse immunoglobulins (Vector Laboratories, Burlingam e, CA) according to the manufacturer instructions. The immunoperoxidase reaction was visualized with 3,39 -diaminobenzidi ne-H Cl (DAB) buffer tablets (Merck, Darmstadt, Germany) or 3-am ino-9-ethylcarbazole (AEC) (Vector Laboratories) and 0.006% H 2 O 2 . The slides were briefly counterstained with hematoxylin and mounted. Negative controls included incubations in which the primary antibodies were omitted.
Combined in situ hybridization and immunohistochemistry
To visualize whether endothelial cells were transduced in vivo with GPE LXflk-1 TM, we perform ed in situ hybridiza-tion as described, followed by immunostaining with von Willebrand factor. After in situ hybridization color development, slides were blocked with serum (Vector Laboratories) and immunohistochem istry using von Willebrand factor (Dakopatts) was performed as described.
Statistical analysis
Statistical analysis was performed using Statistica (StatSoft) software for Kaplan±Meier plots. The log-rank test was used for statistical analysis of survival data. p , 0.001 was considered significant.
RESU LTS
We first compared the survival time of animals coimplanted with GPE LXflk-1TM in different ratios (tumor cells/virus-producing cells) with the survival of control groups (GS-9L alone and GS-9L with GPE LXNULL). The virus-producing cells GPE LXNULL were used as control to exclude unspecific responses in tumor growth due to infection with retroviruses. The results are summ arized in Table 1 . Animals without treatment developed neurological sym ptom s within 12±14 days after tumor cell injection. In animals inoculated with tumor cells and GPE LXflk-1TM (1:0.1, 1:1, and 1:8 ratios) survival was longer than in control rats (Fig. 1) . No survival benefit was observed in animals coimplanted with GS-9L/GPE LXflk-1TM at a ratio of 1:0.01. The effect on survival of tumor-bearing rats was dose dependent, with a maximum achieved when the virus-producing cells were in eightfold excess relative to the tum or cells. Rats treated with flk-1TM virus particle-containing producer cell supernatants (VCS) immediately after tumor cell implantation also exhibited prolonged survival, but to a lesser extent when compared with rats inoculated with virus-producing cells.
We then investigated whether the VEGFR-2 dominant-negative strategy was able to prolong survival in rats with established GS-9L tumors. Animals treated with GPE LXflk-1TM or VCS 5 days after tumor cell inoculation did not show any significant change in survival time, compared with the control group (Table 1; Fig. 1) .
We evaluated whether the VEGFR-2 dom inant-negative strategy could inhibit tumor growth in established tumors in a subcutaneous tumor model. Rats coinoculated with GS-9L and GPE LXflk-1TM at a 1:1 ratio developed small tum ors with 92% tumor growth inhibition. When GPE LXflk-1TM was injected commencing on day 3, 67.5% suppression of tumor growth was observed; 45% tumor growth suppression was observed when the treatm ent was started on day 9 after tumor cell inoculation. No effects on tumor growth were observed when the tumors were inoculated with GPE LXflk-1TM comm encing on days 18 and 36 after tumor cells injection (Fig. 2) .
We investigated further the participation of VEGF sequestration in the dominant-negat ive strategy by inoculating intra-
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FIG . 1. (A)
Kaplan±Meier survival curves of Fischer 344 rats after brain grafting of GS-9L cells alone, or after coimplantation with GPE LXNULL, with different ratios of GPE LXflk-1TM, or with VCS. Survival of rats implanted with GS-9L-flk-1TM was also evaluated. Differences in survival were evaluated by the log-rank test. (B) Kaplan±Meier survival curves of rats with GS-9L tumors treated with a single injection of GPE LXflk-1TM or VCS. Control animals were injected with PBS alone.
Intracerebral implantation of GS-9L tumor cells (4 3 10 5 ) on day 0. Virus-producing cells (3 3 10 cerebrally GS-9L stably transfected with flk-1TM. These cells exhibited growth rates similar to that of the parental cell line in vitro (data not shown); therefore, the effect on tumor growth in vivo cannot be attributed to alteration in tumor cell mitogenesis due to expression of VEGFR-2 or retrovirus integration. GS-9L flk-1TM binds VEGF as determ ined by a 125 I-labeled VEGF-binding assay (data not shown). Rats implanted with GS-9L flk-1TM showed significantly prolonged survival, similar to that obtained in rats coimplanted with an eightfold excess of virus-producing cells relative to tumor cells (Fig. 1) .
Histologically, control animals showed large tumors with well-vascularize d tissue. Necrotic areas were absent. In contrast, GPE LXflk-1TM -coinoculated tum ors showed large areas of necrosis with reduced tumor vascularization (Fig. 3) . Rats injected with GS-9L stably transfected with flk-1TM developed large tumors, with central necrosis. Vascularization of these tumors was greatly impaired, since only a few vessels around necroses were observed (Fig. 3) . Little immunoreactiv ity was observed for monocyte-mac rophage and T cell markers in all tumors studied (data not shown).
Detection of neo r and VEGFR-2 in tumors
To detect infection rates of treated tumors we performed in situ hybridization with neo r and VEGFR-2. The efficacy of gene transfer was proportional to the number of implanted virus-producing cells in the coimplantation experiments. Using the gene marker neo r , we observed that the majority of transduced cells were tum or cells. At the time point of tum or removal, endothelial cells were sporadically positive for neo r (Fig. 4a and  b) . Dominant-nega tive VEGFR-2-inhibited tum ors expressed neo r in tum or cells ( Fig. 4c and d) , which matched the result obtained with a VEGFR-2-specific probe (flk-1) ( Fig. 4e and  f) . Endogenous VEGFR-2 expression in tumor endothelial cells was confirmed by in situ hybridization (data not shown). In situ hybridization of GS-9L flk-1TM tum ors with an flk-1 probe confirmed VEGFR-2 expression ( Fig. 4g and h) . In tumors treated with GPE LXflk-1TM and VCS 5 days after tumor cell implantation, transduction efficiency was low, with only focal neo r -positive signals (data not shown).
Detection of gene marker in peripheral organs
To determine whether transduction of peripheral organs occurs after intracerebral inoculation of virus-producing cells, genomic DNA was isolated from tumors (as positive control), contralateral brain, heart, liver, lung, kidney, and spleen after the animals died. Using Southern blot analysis for neo r gene, we could detect specific hybridization signals only in treated tumors (data not shown). In addition, we performed PCR analysis for neo r to detect retrovirus sequences that were present but below the level of Southern blot detection sensibility. We amplified neo r marker gene in all organs studied. Variability in hybridization signals existed between animals, but since this was not a quantitative study, the differences may have been due to DNA loading or variations in amplification efficiency. In rats 6 GPE LXflk-1TM cells every 3 days, with the beginning of treatment being at different time points for each group: day 0 (group II), day 3 (group III), day 9 (group IV), day 18 (group V), and day 36 (group VI). Tumors were rem oved on day 39. Control tum ors were injected with PBS (group I). implanted with GPE LXflk-1TM only, we found neo r sequences predominantly in lung and spleen at 3 months postinjection. At 6 months postinjection no specific amplification of neo r gene was found in any tissue (Fig. 5) . To identify the cells positive for retroviral vector sequences, in situ hybridization analyses were carried out on tissues that were strongly positive for neo r gene on PCR analysis. None of these tissues showed detectable mRNA levels for neo r (data not shown). Histological analysis of these tissues showed no morphological abnormalities (data not shown).
DISC USSION
Our study shows prolonged survival when GS-9L tum or cells and virus-producing cells expressing a truncated VEGFR-2 were coinjected into rat brains. The morphological features of tum ors, such as necrosis and decreased tissue vascularization, suggest that angiogenesis was successfully impaired in this model. On the other hand, tumors injected with control vector virus producer cells were highly vascularized, indicating that tum or neovascularization was not affected by the presence of these cells or by infection with retrovirus. Moreover, null vector virus-producing cells did not have any protective effect on survival of the rats.
The survival was prolonged in a dosage-dependent manner in coimplantation studies. Virus-concentrat ed supernatant also suppressed tumor growth and prolonged survival time, but to a lesser extent as observed when virus-producing cells were coimplanted. Under these experimental conditions, virus-producing cells or retroviruses were in close contact with target cells and transduction efficiency was likely to be high.
We next implanted virus producer cells or virus-concentrated supernatant in established intracerebral tum ors, a experimental setting that mimicks more closely the clinical situation in humans. On day 5 after tumor cell inoculation, rats received an intratumoral injection of GPE LXflk-1TM or VCS. No changes in survival time were observed in the treated groups. Using in situ hybridization with a neo r probe, we observed a low level of transduction that was restricted to a small tumor zone. It is well established that the transduction of target cells using retroviral vectors occurs in the immediate vinicity of virus-producing cells, since the diffusion of virus particles is limited in the tum or extracellular matrix (Puumalainen et al., 1998) . Thus, at the time point of treatment tum ors might already be too large to achieve efficient transduction. Even if optimal gene transduction could be obtained in this setting, a syngeneic 9L intracerebral glioma may grow too fast (median survival, 12 days) for cytostatic rather than cytotoxic therapy.
We further examined the influence of tum or size on the therapeutic efficacy of VEGFR-2 dominant-negat ive retroviral treatment in a subcutaneous tumor model. Significant growth inhibition was observed when an equal ratio of tumor cells and virus-producing cells was used. Delayed treatment starting on day 3 or on day 9 also suppressed tum or growth (67.5 and 45%, respectively). In the later treatment groups (treatment commencng on day 18), the failure of tum or growth inhibition most likely represents inadequate gene transfer since in large tumors, a large fraction of tum or and endothelial cells escaped transduction. Taken together, these results emphasize the limits of retrovirus-m ediated gene therapy protocols.
Relatively few endothelial cells were found to coexpress neo r and von Willebrand factor. The majority of transduced cells were tumor cells. This observation raised the possibility that in addition to dominant-negat ive receptor inhibition, VEGF depletion by VEGFR-2-expressing tumor cells could participate in the antiangiogeneic effect. We therefore implanted GS-9L cells stably transfected with the truncated VEGFR-2. In this setting, which mimicks an optimal situation of in vivo gene transfer to tumor cells, but will leave endothelial cells untransduced, rats exhibited a rate of survival similar to that of animals treated with high numbers of GPE LXflk-1TM . Morphologically, tumors showed a similar phenotype of impaired angiogenesis with large necrotic areas and few tumor capillaries. GS-9L flk-1TM expressed the extracellular domain from VEGFR-2 at the cell surface and could therefore bind VEGF, reducing the amount of VEGF available to endothelial cells. Several gene therapy strategies have been developed in order to interfere with the normal function of endothelial cell receptors (Goldman et al., 1998; Lin et al., 1998) . Kong et al. (1998) showed that an adenovirus encoding soluble VEGFR-1 substantially suppresses tumor metastasis. The authors suggested that the soluble VEGFR-1 might interact with endogenous VEGFR-1 and VEGFR-2, forming inactive heterodimeric receptors; alternatively, the soluble receptor could sequester VEGF.
Thus, dom inant-negative strategies for VEGFR-1 and VEGFR-2 may act not only in a cis fashion, which would require gene transfer to all endothelial cells within the tum or, but also in a trans, ª bystanderº fashion: depletion of VEGF may induce vessel regression, since VEGF has been shown to act as a vascular survival factor (Alon et al., 1995; Benjamin and Keshet, 1997; Hanahan, 1997) . Our results are consistent with this hypothesis and suggest that VEGF sequestration may be an important mechanism in vivo when retrovirus encoding a truncated VEGFR-2 is inoculated within tum ors. The use of vectors with endothelial cell-specific promoters or vector delivery directly into the blood stream may improve endothelial cell transduction and therefore the participation of receptor heterodimerization in the VEGFR-2 dom inant-negative strategy.
Toxicity studies
Replication-defe ctive retroviral vectors have been extensively used in animal models and in more than 100 early-phase hum an clinical trials to deliver the transgene of interest (for reviews see Anderson, 1992; Miller, 1992; Ross et al., 1996) . Retroviral vectors are incorporated selectively into the genome of dividing cells. Within the brain, intratum oral injection of retroviruses will transduce only the proliferating cell pool, e.g., tumor and endothelial cells (Culver et al., 1992) . However, one theoretical concern associated with the use of retroviral vectors for gene therapy is the possibility that these vectors induce transduction of remote, nontarget tissues.
In this study promiscuous transduction of nontarget tissues was monitored using Southern blot analysis and PCR assay. Southern blot analysis of the samples did not reveal any vector sequences in peripheral organs. By using PCR, vector sequences were detected in all tissues exam ined (contralateral brain, heart, lung, kidney, liver, and spleen). Rats sacrificed 6 months after inoculation of GPE LXflk-1TM did not exhibit vector sequences in the organs studied. To verify the cell types that were positive for vector sequences, in situ hybridization analysis was perform ed. No specific signal was found in any tissue. It is possible that mRNA transcripts levels for neo r were too low to be detected by in situ hybridization. Alternatively, the LTR promoter could be shut down by the host cell.
The blood±brain barrier could minimize the spread of retroviruses or virus-producing cells, but it is well known that the barrier is significantly disrupted in brain tumors. Murine virusproducing cells could pass through the blood±brain barrier into the peripheral blood. It has been shown that murine retroviruses or murine cells are not destroyed in serum from nonprimate species, including rats (Rollins et al., 1996) . Thus, promiscuous transduction can occur, owing either to circulating virusproducing cells or to circulating retroviruses in a rat model. However, this situation is not expected to be found in humans, since in peripheral blood of prim ates the survival of murine cells and retrovirus vectors is limited owing to inactivation by the com plem ent-mediated immune response . Several studies dealing with the safety of retroviral vectors in gene therapy showed no retroviremia or pathology in long-term follow-up of primates exposed to murine amphotropic retrovirus (Cornetta et al., 1989) . We also did not find any morphological change in the peripheral organs that could be related to the integration of retrovirus sequences. Still, a further concern associated with the use of retroviral vectors in gene therapy is the possibility that these vectors can induce oncogenesis by insertional mutagenesis (Temin, 1990) . Additional long-term studies on this subject are certainly warranted.
In conclusion, antiangiogenic gene therapy using a dominant-negative VEGFR-2 strategy is a feasible approach to control brain tumor growth if gene delivery can be improved. Our results suggest a dual mode of function, namely inhibition of endogenous VEGFR-2 function and VEGF depletion. The use of other vector systems or intravascular delivery of cationic liposome-DNA complexes may improve endothelial cell transduction. Although inadvertent transduction of nontarget organs could be detected in a rat model, no pathological changes were observed in transduced tissues. Therefore, the dominant-negative VEGFR-2 strategy in brain tum ors is not expected to be associated with significant toxicity.
